Binding Database

BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

16 articles for HP Beck

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.

Amgen

Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.

Amgen

Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.

Amgen

Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

Amgen

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Amgen

Rational design and binding mode duality of MDM2-p53 inhibitors.

Amgen

Structure-based design of novel inhibitors of the MDM2-p53 interaction.

Amgen

Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.

Amgen

Spiroindolones, a potent compound class for the treatment of malaria.

Swiss Tropical and Public Health Institute

Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T

Rapt Therapeutics

Benzamide derivative compound, method for preparing same, and pharmaceutical composition for treating or preventing inflammatory disease containing same as active ingredient

Seoul National University R&D Foundation

Heterocyclic compounds for inhibiting TYK2 activities

Beijing Innocare Pharma Tech

Tricyclic compounds as Cyp1 inhibitors

The General Hospital

Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases

Merck Sharp & Dohme

Discovery of a Highly Selective STK16 Kinase Inhibitor.

Chinese Academy of Sciences

Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases.

University of Wisconsin